Clinical Trial Update: A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating safety, tolerability, and pharmacokinetics of nivolumab in Chinese patients with previously treated advanced or recurrent solid tumor…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Solid Tumors | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-10-24